Renaissance Technologies - CHINA BIOLOGIC PRODS HLDGS I ownership

CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 86 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2017. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q4 2020$74,030,000
-21.0%
626,789
-25.7%
0.08%
-14.9%
Q3 2020$93,694,000
+47.1%
843,027
+35.3%
0.09%
+70.9%
Q2 2020$63,673,000
+134.7%
623,141
+147.9%
0.06%
+111.5%
Q1 2020$27,133,000
+410.1%
251,396
+450.1%
0.03%
+550.0%
Q4 2019$5,319,000
+209.8%
45,700
+204.7%
0.00%
+300.0%
Q3 2019$1,717,000
+98.0%
15,000
+64.8%
0.00%0.0%
Q2 2019$867,000
-69.4%
9,100
-70.6%
0.00%
-66.7%
Q1 2019$2,829,000
+360.0%
31,000
+282.7%
0.00%
+200.0%
Q4 2018$615,000
-86.0%
8,100
-85.2%
0.00%
-80.0%
Q3 2018$4,384,000
-79.4%
54,800
-76.7%
0.01%
-58.3%
Q2 2018$21,325,000
+135.7%
235,300
+110.7%
0.01%
+20.0%
Q1 2018$9,048,000
+12.3%
111,700
+9.2%
0.01%
+11.1%
Q4 2017$8,058,000
-56.8%
102,300
-49.4%
0.01%
-59.1%
Q3 2017$18,648,000202,1000.02%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q3 2017
NameSharesValueWeighting ↓
Kite Lake Capital Management (UK) LLP 301,773$30,835,00047.96%
Maso Capital Partners Ltd 948,629$96,931,00039.10%
Athos Capital Ltd 269,832$27,571,00018.83%
York Capital Management Global Advisors, LLC 1,347,897$137,728,0009.09%
Sand Grove Capital Management LLP 351,661$35,933,0006.83%
HHLR ADVISORS, LTD. 2,962,076$302,665,0002.77%
Ovata Capital Management Ltd 37,000$3,781,0001.13%
Temasek Holdings (Private) Ltd 1,240,000$126,703,0000.76%
Pentwater Capital Management LP 399,570$40,828,0000.73%
Campbell & CO Investment Adviser LLC 2,200$225,0000.28%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders